Protagonist Therapeutics, Inc. (PTGX)
Nasdaq · Healthcare · Biotechnology
$140.63+0.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.1B
- P/E (trailing)
- 136.5
- 52-week range
- $62.24 – $160.81
- 52-week change
- +113.93%
- EPS (trailing)
- $1.03
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $46.0M (−89.41%)
- Net income
- −$130M
- Operating margin
- −343.6%
- Diluted EPS
- −$2.05
- Free cash flow
- $56.1M
From the company’s annual report on SEC EDGAR.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Headquarters: Newark, United States · 141 employees · protagonist-inc.com